The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ARCELLX INC COMMON STOCK 03940C100   68,981,628 1,047,557 SH   SOLE   1,047,557 0 0
CARISMA THERAPEUTICS INC COM 14216R101   281,299 718,332 SH   SOLE   718,332 0 0
KYMERA THERAPEUTICS INC COM 501575104   19,946,055 457,059 SH   SOLE   457,059 0 0
RAPT THERAPEUTICS INC COM NEW 75382E109   99,496 12,437 SH   SOLE   12,437 0 0
RALLYBIO CORP COM 75120L100   255,081 754,678 SH   SOLE   754,678 0 0
SEER INC COM CL A 81578P106   1,747,043 816,375 SH   SOLE   816,375 0 0
SUTRO BIOPHARMA INC COM 869367102   124,933 175,000 SH   SOLE   175,000 0 0
XILIO THERAPEUTICS INC COM 98422T100   453,998 667,742 SH   SOLE   667,742 0 0